We are live on ! Find out more
APVO icon

Aptevo Therapeutics
APVO

2 hedge funds and large institutions have $352K invested in Aptevo Therapeutics in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2 → 2 (0)

0% less ownership

Funds ownership: 0% → 0% (-0%)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

69% less capital invested

Capital invested by funds: $1.13M → $352K (-$774K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
2
Holders Change
–
Holders Change %
0%
% of All Funds
0.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
1
Calls
$8K
Puts
–
Net Calls
+$8K
Net Calls Change
+$8K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$142K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$283K
2
SM
Sabby Management
Florida
-$142K
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$16K
4
EARNEST Partners
EARNEST Partners
Georgia
-$5
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$94K +$142K +1 New
SM
2
Sabby Management
Florida
$63.3K -$142K -1 -50%
Citadel Advisors
3
Citadel Advisors
Florida
$47.4K – – –
SSA
4
Schonfeld Strategic Advisors
New York
$28.8K – – –
Squarepoint
5
Squarepoint
New York
$25.1K – – –
Millennium Management
6
Millennium Management
New York
$18.9K – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$16.6K – – –
AC
8
Armistice Capital
New York
$11.1K -$283K -2 Closed
CF
9
Cantor Fitzgerald
New York
$10.6K – – –
BlackRock
10
BlackRock
New York
$8.44K – – –
Geode Capital Management
11
Geode Capital Management
Massachusetts
$7.82K – – –
Morgan Stanley
12
Morgan Stanley
New York
$4.12K – – –
Northern Trust
13
Northern Trust
Illinois
$2.56K – – –
TRCT
14
Tower Research Capital (TRC)
New York
$2.47K – – –
TSS
15
Two Sigma Securities
New York
$2.04K – – –
BBA
16
Baader Bank Aktiengesellschaft
Germany
$2.03K – – –
Franklin Resources
17
Franklin Resources
California
$1.99K – – –
State Street
18
State Street
Massachusetts
$1.98K – – –
DWA
19
Divergent Wealth Advisors
Utah
$1.81K – – –
JP Morgan Chase
20
JP Morgan Chase
New York
$343 – – –
Wells Fargo
21
Wells Fargo
California
$293 – – –
Fifth Third Bancorp
22
Fifth Third Bancorp
Ohio
$53 – – –
PNC Financial Services Group
23
PNC Financial Services Group
Pennsylvania
$26 – – –
TC
24
Truvestments Capital
Florida
$17 – – –
Osaic Holdings
25
Osaic Holdings
Arizona
$5 – – –
1
2

APVO Hedge Fund Activity: Q4 2023 in Review

2 of the 6,862 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q4 2023, worth a combined $352K — down 69% from $1.13M a quarter earlier.

Fund positioning in APVO was balanced in Q4 2023: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 1 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $142K. The largest seller was Armistice Capital, exiting entirely with an estimated $283K sold.

  • 2 institutional investors held Aptevo Therapeutics (APVO) as of Q4 2023, unchanged from Q3 2023.
  • Funds reported $352K of Aptevo Therapeutics stock for Q4 2023, down 69% quarter-over-quarter.
  • 1 fund opened new Aptevo Therapeutics positions in Q4 2023 and 1 closed out, a net change of 0 holders.
  • The largest Aptevo Therapeutics buyer in Q4 2023 was Renaissance Technologies, an estimated $142K added.
  • The largest Aptevo Therapeutics seller in Q4 2023 was Armistice Capital, an estimated $283K sold.

Based on aggregated 13F filings for Q4 2023.